Angiotensin I
Invokana for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease
The SGLT2 inhibitor Canagliflozin ( Invokana ) .... as an adjunct to the standard of care in adults with type...
The combination Sacubitril and Valsartan does not significantly reduce hospitalizations and cardiovascular death in patients with heart failure with preserved ejection fraction
The number of patients with heart failure with preserved ejection fraction is on the rise, and the search is on...
PIONEER-HF trial: angiotensin-neprilysin inhibition in acute decompensated heart failure
Acute decompensated heart failure accounts for more than 1 million hospitalizations in the United States annually. Whether the initiation of...
Canagliflozin reduces major cardiovascular events and kidney failure in patients with type 2 diabetes and chronic kidney disease
Results of a new subgroup analysis from the phase 3 CREDENCE study, showing Canagliflozin ( Invokana ) has significantly reduced...
PARAGON-HF trial in heart failure patients with preserved ejection fraction: Entresto misses statistical significance on the primary endpoint
The results from the global phase III PARAGON-HF study, investigating the safety and efficacy of Sacubitril / Valsartan ( Entresto...
Lokelma for the treatment of adults with hyperkalaemia: approved in European Union
The European Commission has granted marketing authorisation for Lokelma ( formerly ZS-9, sodium Zirconium cyclosilicate ) for the treatment of...
CHAMP-HF Registry: medical therapy for heart failure with reduced ejection fraction
Guidelines strongly recommend patients with heart failure with reduced ejection fraction ( HFrEF ) be treated with multiple medications proven...
Entresto, a combination of Sacubitril and Valsartan, can be initiated early in hospitalized patients after an acute heart failure episode
Data from the TRANSITION study presented at the European Society of Cardiology ( ESC ) Congress in Munich ( Germany...
Cardiovascular complications associated with cancer therapy
Anthracycline-induced cardiotoxicity was first reported in early 1970s. Since then, there has been increasing recognition of its association with poor...
Angiotensin converting enzyme inhibitors and risk of lung cancer
The aim of a population-based cohort study was to determine whether the use of angiotensin converting enzyme inhibitors ( ACEIs...
Chymase inhibitor Fulacimstat in patients with left ventricular dysfunction after myocardial infarction: safety and tolerability
The chymase inhibitor Fulacimstat is developed as a first-in-class treatment option for the inhibition of adverse cardiac remodeling in patients...
Heart failure - Cognition- and dementia-related adverse effects with combination of Sacubitril and Valsartan: analysis of the FAERS database
Because neprilysin is involved in the degradation of amyloid-beta, there is concern that the angiotensin-neprilysin inhibitor Sacubitril - Valsartan (...
Heart failure with reduced ejection fraction: dementia-related adverse events with angiotensin receptor-neprilysin inhibitor Entresto versus Enalapril
Inhibition of neprilysin, an enzyme degrading natriuretic and other vasoactive peptides, is beneficial in heart failure with reduced ejection fraction...
LCZ696, a combination of Sacubitril and Valsartan, has a cardio-protective effect against myocardial infarction
The new drug LCZ696 is a treatment for chronic heart failure. LCZ696 is better than conventional drugs at reducing cardiac...
Heart failure and reduced ejection fraction: Sacubitril associated with Valsartan over angiotensin-converting enzyme inhibitors
The quality of evidence regarding patient-centered outcomes in adults with heart failure after Sacubitril combined with Valsartan ( Entresto )...
Cardiotoxicity associated with targeted cancer therapies
Compared with traditional chemotherapy, targeted cancer therapy is a novel strategy in which key molecules in signaling pathways involved in...
ESC Guidelines on acute and chronic heart failure: Entresto included for the first time and new heart failure category added
European Society of Cardiology ( ESC ) Guidelines for the diagnosis and treatment of acute and chronic heart failure are...
FDA strengthens kidney warnings for diabetes medicines Canagliflozin and Dapagliflozin
The FDA ( Food and Drug Administration ) has strengthened the existing warning about the risk of acute kidney injury...
Empagliflozin significantly reduces the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
New data showed Empagliflozin ( Jardiance ) reduces the risk for new-onset or worsening kidney disease by 39% versus placebo...
RESPONSIfVE trial: effectiveness and tolerability of Ivabradine with or without concomitant beta-blocker therapy in patients with chronic stable angina
In the prospective, open-label, non-interventional, multicenter RESPONSIfVE study, the effectiveness, response rates and tolerability of Ivabradine ( Corlentor, Procoralan )...